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Small renal masses are increasingly diagnosed inciden-
tally. This results in management dilemma because at
histopathology significant numbers of small renal masses
are either benign tumors such as angiomyolipoma (AML)
or oncocytoma, or are neoplasms with relatively indolent
behavior [1]. Surgical treatments such as partial and total
nephrectomy although provide excellent oncologic con-
trol is associated with development and worsening of
renal insufficiency and associated cardiovascular morbid-
ity [2]. Therefore, ability to non-invasively investigate
renal tumor histopathology and aggressiveness can guide
treatment decision and lower treatment cost.
Within this paradigm, the role of radiologist and ima-
ging is evolving from traditional role of identifying renal
lesion and detecting enhancement, to predicting aggres-
siveness and biology of the tumor as well as providing
operative guidance. MR imaging can play a very impor-
tant role not only as a problem solving tool in traditional
sense by detecting subtle enhancement and macroscopic
and microscopic fat, but can provide deeper insight into
tumor biology. Number of key observations highlighting
the role of MR in evaluation of renal masses is as listed
below:
1. Differentiating benign renal masses from
malignant tumors
- There is some controversy regarding the role of
signal loss on opposed phase chemical shift imaging
in discriminating AML from RCC [3,4].
- Lipid poor AML tend to have uniform low T2 sig-
nal and uniform enhancement without evidence for
necrosis [5,6].
- There is overlap in the morphologic features of Onco-
cytoma and RCC on conventional imaging [7]. Further-
more segmental enhancement inversion is noted in
oncocytoma as well as other renal neoplasms [8].
2. Histologic subtyping RCC
- Papillary subtype of RCC usually have low T2 signal
and are hypovascular when compared to clear cell
RCC. Furthermore, clear cell subtype have heteroge-
neous T2 signal and demonstrate heterogeneous
hypervascularity [9].
- Chromophobe subtype is difficult to differentiate
from clear cell RCC on the basis of enhancement.
However, advance diffusion and perfusion MR techni-
ques have shown some promise [10].
3. Predicting tumor aggressiveness/outcome
- Cystic RCC with less than 25% solid enhancing
component tend to be less aggressive than solid
RCC [11].
- High stage clear cell RCC tend to me more heteroge-
neous with different texture compared to low stage
RCC on Apparent diffusion coefficient (ADC) map [12].
- High grade clear cell RCC tend to have lower ADC
compared to low grade clear cell RCC [13].
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